Guimaraes, Julio Brandao
Nevitt, Michael C.
McCulloch, Charles E.
Schwaiger, Benedikt J.
Gersing, Alexandra S.
Facchetti, Luca
Bucknor, Matthew D.
Chanchek, Nattagan
Liu, Felix
Joseph, Gabby B.
Link, Thomas M.
Funding for this research was provided by:
National Institutes of Health (N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, N01-AR-2-2262)
Article History
Received: 13 March 2017
Revised: 11 July 2017
Accepted: 30 August 2017
First Online: 6 October 2017
Compliance with ethical standards
:
: The scientific guarantor of this publication is Thomas Link.
: The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.
: The OAI is a public–private partnership comprised of five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Pfizer, Inc.; Novartis Pharmaceuticals Corporation; Merck Research Laboratories; and GlaxoSmithKline. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This manuscript received the approval of the OAI Publications Committee based on a review of its scientific content and data interpretation.
: Charles E. McCulloch, Ph.D. kindly provided statistical advice for this manuscript.
: Written informed consent was obtained from all subjects (patients) in this study.Written informed consent was waived by the institutional review board.
: Institutional review board approval was obtained.
: • prospective• diagnostic or prognostic study• multicentre study